() () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () ()

Viridium begins pot capsule sales through Broken Coast

Viridium begins pot capsule sales through Broken Coast


Viridium Pacific Group Ltd.'s wholly owned subsidiary, EFX Laboratories Inc., has commenced medical two-piece capsule sales through its partnership with Broken Coast Cannabis Ltd., a wholly owned subsidiary of Aphria Inc., available to BCC medical clientele through its on-line sales portal.



Under the terms of the agreement between EFX and Aphria, the agreement enables EFX to provide commercial manufacturing services with a revenue-sharing structure on the medical two-piece capsule containing various THC (tetrahydrocannabinol) and CBD (cannabidiol) concentrations.

The first available product under the partnership structure is a five-milligram THC capsule using a custom blend of BCC high-quality THC strains. This product offering gives medical clients a dose-controlled, predictive, tasteless, odourless and discreet option of consuming cannabis oil. Additionally, the whole-flower, full-spectrum capsule is one of the only available in the Canadian cannabis market resulting in a unique selling position. Commercial production is now under way and the product is available on Broken Coast and Aphria's website for their registered patients to purchase.

The realization of a commercial medical pill is a significant milestone for EFX and a step toward our vision to provide the market value-added products

stated Jay Garnett, Viridium's chief executive officer.

About Viridium Pacific Group Ltd.

Viridium is the parent company of Experion Biotechologies Inc., a Health Canada-licensed cultivation and processor of cannabis, based in Mission, B.C., and EFX, a medical products production and clinical research company based out of Calgary, Alta.

Viridium is invested in a portfolio of products, including a full spectrum of consumer needs, including products for adult use, wellness and therapeutic daily use.

© 2019 Canjex Publishing Ltd. All rights reserved.


Comments are closed.